# AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

> **NCT00770848** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 162 (actual)

## Conditions studied

- Cancer
- Castrate-Resistant Prostate Cancer
- Mestastatic Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** AMG 102
- **DRUG:** AMG 102
- **DRUG:** Mitoxantrone
- **DRUG:** Placebo
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00770848
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-01
- **Final completion:** 2012-04
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2014-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770848, "AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00770848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*